A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
A-phase II study of intravenous 6-thioguanine (NSC-752) in multiple myeloma. A Southwest Oncology Group study.
复制标题
静脉注射 6-硫鸟嘌呤 (NSC-752) 治疗多发性骨髓瘤的 A 期 II 研究。
DOI：
10.1007/bf00171990
复制
发表时间：
1990
影响因子：
3.4
通讯作者：
Ungerleider,JS
中科院分区：
文献类型：
--
作者：
Edelstein,MB;Crowley,JJ;Valeriote,FA;Bonnet,JD;Carden,JO;Khanna,RC;Salmon,SE;Ungerleider,JS
33例复发或难治性多发性骨髓瘤患者接受6-硫鸟嘌呤（6TG）治疗，剂量为lg/M2，每三周治疗4小时。主要毒性为骨髓毒性；血小板减少症比中性粒细胞减少症更常见。1例患者达到PR， 2例临床改善。在短时间内输注6TG被证明具有髓毒性，但在先前治疗过的骨髓瘤患者中表现出很少的活性。
Thirty-three patients with relapsing or refractory multiple myeloma were treated with 6-Thioguanine (6TG) at a dose of lg/M2, with therapy given over four hours every three weeks. The major toxicity seen was myelotoxicity; thrombocytopenia was more commonly noted than neutropenia. One patient achieved a PR, two were clinically improved. 6TG in this short infusion schedule proved to be myelotoxic, but demonstrated little activity in previously treated myeloma patients.